EVAX

Evaxion Biotech A/S [EVAX] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

EVAX Stock Summary

Top 10 Correlated Stocks

EVAX

In the News

EVAX Financial details

Company Rating
-
Market Cap
15.54M
Income
-22.16M
Revenue
73.6K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
63
Optionable
No
Shortable
Yes
Earnings
29 May 2024
P/E
-0.81
Forward P/E
-
PEG
0.51
P/S
-
P/B
-0.22
P/C
-
P/FCF
1.52
Quick Ratio
-
Current Ratio
-
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-8.24
EPS next Y
-
EPS next Q
-
EPS this Y
-17.24%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-18.54%
-
-
-
-
SMA20
-1.35%
SMA50
42.23%
SMA100
122.81%
Inst Own
-
Inst Trans
-
ROA
33%
ROE
41%
ROC
0.32%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.824-18.5
52W High
-65.42%
52W Low
+211.25%
RSI
55.57
Rel Volume
0.1
Avg Volume
701.1K
Volume
70.02K
Perf Week
22.06%
Perf Month
8.07%
Perf Quarter
154.08%
Perf Half Y
115.4%
-
-
-
-
Beta
-0.016
-
-
Volatility
0.52%, 0.48%
Prev Close
-3.49%
Price
6.225
Change
-4.08%

Something similar

Top by Market Cap
TL0.DE
0YXG.L
BRK-A
AMZ.DE
MSFT
Same Sector
EQUR
KDEV.ST
ADIL
TUB.BR
CSLLY
Top Correlated Stocks
CRDF
VRM
BMRA
GLW
NP
Similar Market Cap
CYCN
RAFI
BBY.DE
IPW
AKU

Company Profile

Healthcare Biotechnology
  • Volume Average 701.1K
  • Market Capitalization 15.54M
  • Employee 63
  • CEO Mr. Christian Kanstrup M.Sc.
  • Headquarters Horsholm,DK
  • IPO Date 2021-02-05
  • Website https://www.evaxion-biotech.com

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.